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LETTERS TO THE EDITORPATIENTS WITH CANCER
AND CENTRAL PULMONARY
EMBOLI TREATED
SURGICALLY
To the Editor:
We read with great interest the recent
article by Greelish and colleagues,1
‘‘Improved Midterm Outcomes for
Type A (Central) Pulmonary Emboli
Treated Surgically,’’ which has the po-
tential to change the landscape of indi-
cations for surgical intervention in
acute central pulmonary embolism.
The volume of acute pulmonary embo-
lectomy cases completed at our institu-
tion would significantly increase if we
used the treatment algorithm proposed.
Specifically, we refer to the algorithm
for patients without the classic indica-
tions for surgical intervention and
moderate to severe right ventricular dys-
function according to 2-dimensional
echocardiography. Currently at the Ot-
tawa Heart Institute, our patients under-
going acute pulmonary embolectomy
patients are limited to those in extremis
with the classic indications outlined in
by Greelish and colleagues,1 with resul-
tant poor survival outcomes overall. If
our indications for surgical intervention
were tobebroadened to includeall those
with a central pulmonary embolism and
moderate to severe right ventricular dys-
function, by expanding the scope of care
for this critically ill group an important
associated cost burden would be placed
on our already limited operating room
and surgical intensive care unit
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The JournalIn light of the potential increase
in surgical volume and associated
resource use cost, we consider it im-
portant to eliminate additional con-
founders from the survival analysis.
In particular the differences between
the medical and surgical management
groups with respect to history of can-
cer must be reexamined. It would be
of great value to complete Kaplan-
Meier life table analysis for both
groups, excluding all patients with can-
cer from analysis. Active malignancy
is an important confounder for all
cause death rates and subsequent life
table analysis. The presence of active
or incurable cancer would certainly in-
fluence patient management in both
subtle and overt ways, the most overt
way being that a patient with meta-
static or locally advanced cancer in
less likely to be considered for aggres-
sive surgical management. An addi-
tional important point is that
regardless of whether patients with
cancer die directly of their disease,
the very presence of malignancy puts
them at risk for death from other asso-
ciated conditions, including thrombo-
embolism, infection, myocardial
infarction, hemorrhage, and stroke.2-4
We understand it was stated that
only 1 patient in the surgical treat-
ment group and 23 in the medically
treated group died of cancer.1 We
still recommend that the survival
analysis be completed to exclude
this confounding group, however,
because the presence of cancer
influences patient management and
puts patients at risk for death
from other malignancy associated
conditions.2-4
We anticipate with great interest the
results from the survival analysis
excluding patients with cancer. If
there is still a survival difference
evident after exclusion of patients
with cancer, Greelish and colleagues’
article1 truly has the potential to
change the scope of surgery for acute
pulmonary embolectomy by broaden-
ing our indications for surgical
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We appreciate the comments of
McGuire and Rubens on our article
regarding the proposed new algorithm
for surgical management of central
surgically accessible (Vanderbilt type
A) pulmonary embolism. In our arti-
cle,1 we documented that active ma-
lignancy was a confounding variable
for survival. Certainly, in a patient
with metastatic cancer or locally ad-
vanced malignancy, the decision to
proceed with aggressive surgical man-
agement should be undertaken only
after careful consideration. In our
study, among patients treated surgi-
cally, 2 had active malignancy and 1
died during follow-up as a result of
the cancer. In the medically treated
group, the incidence of cancer at the
time of diagnosis of pulmonary embo-
lism was higher but not significantly
so (32% vs 13%; P ¼ .135). Had
we excluded all patients with a diagno-
sis of cancer at the time of diagnosis of
pulmonary embolism, we would have
excluded 34 patients (32 in the medi-
cal group and 2 in the surgical group),
leaving for analysis a very smallry c Volume 144, Number 3 735
